IMVT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMVT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Immunovant's retained earnings for the quarter that ended in Dec. 2023 was $-750.36 Mil.
Immunovant's quarterly retained earnings declined from Jun. 2023 ($-640.28 Mil) to Sep. 2023 ($-698.95 Mil) and declined from Sep. 2023 ($-698.95 Mil) to Dec. 2023 ($-750.36 Mil).
Immunovant's annual retained earnings declined from Mar. 2021 ($-198.66 Mil) to Mar. 2022 ($-355.39 Mil) and declined from Mar. 2022 ($-355.39 Mil) to Mar. 2023 ($-566.35 Mil).
The historical data trend for Immunovant's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant Annual Data | |||||||||||
Trend | Dec18 | Mar20 | Mar21 | Mar22 | Mar23 | ||||||
Retained Earnings | - | -91.23 | -198.66 | -355.39 | -566.35 |
Immunovant Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Retained Earnings | Get a 7-Day Free Trial | -506.92 | -566.35 | -640.28 | -698.95 | -750.36 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Immunovant (NAS:IMVT) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
William L. Macias | officer: Chief Medical Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Eva Renee Barnett | officer: Chief Financial Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Julia G. Butchko | officer: Chief Dev. & Tech. Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Peter Salzmann | director, officer: Chief Executive Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Andrew J. Fromkin | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139 |
George V Migausky | director | C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Mark S. Levine | officer: Chief Legal Officer | 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Jay S Stout | officer: Chief Technology Officer | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Frank Torti | director | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Douglas J. Hughes | director | C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134 |
Rita Jain | officer: Chief Medical Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Michael James Elliott | officer: Chief Scientific Officer | 320 WEST 37TH STREET, NEW YORK NY 10018 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
From GuruFocus
By Marketwired • 09-28-2023
By PRNewswire • 09-26-2023
By GlobeNewswire • 09-28-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By Marketwired • 09-26-2023
By Marketwired • 08-10-2023
By GuruFocus Research • 10-05-2023
By PRNewswire • 09-28-2023
By GuruFocus Research • 10-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.